<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00692887</url>
  </required_header>
  <id_info>
    <org_study_id>PHP-POST-01</org_study_id>
    <nct_id>NCT00692887</nct_id>
  </id_info>
  <brief_title>Correlation Between Visual Field Defects on Foresee Preferential Hyperacuity Perimeter(PHP) and on Optical Coherence Tomography (OCT) in Patients With Choroidal Neovascularization (CNV)</brief_title>
  <acronym>PHP</acronym>
  <official_title>Correlation Between Visual Field Defects on Foresee PHP and OCT in Patients With CNV Before and After Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Notal Vision Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Notal Vision Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study come to investigate the correlation between visual fields (VF) defects map generated by&#xD;
      preferential hyperacuity perimeter (PHP) and features of the choroidal neovascular lesions&#xD;
      (CNV) demonstrated by Optical Coherence Tomography(OCT).&#xD;
&#xD;
      To investigate the Foresee PHP ability to asses treatment progression post treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Foresee PHP is used in the recent years to detect Age-related Macular Degeneration (AMD)&#xD;
      lesions. The device is capable of differentiation as to stages of AMD and early detection of&#xD;
      changes including choroidal neovascularization (CNV) The Foresee PHPâ„¢ demonstrates a high&#xD;
      level of sensitivity and specificity as to the different stages of AMD including newly&#xD;
      diagnosed or early detection of CNV.&#xD;
&#xD;
      The OCT May be use as well to identify choroidal neovascularization (CNV). Comparison between&#xD;
      the two methods will allow better understanding of both devices.&#xD;
&#xD;
      The Foresee PHP can use as an assessment tool for the progression and success of the&#xD;
      treatment given to AMD lesions. Therefore, evaluation the size and the location of the&#xD;
      treated lesions may serve as an additional tool.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">January 2009</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To investigate the correlation between visual fields (VF) defects map generated by preferential hyperacuity perimeter (PHP) and features of the choroidal neovascular lesions (CNV) demonstrated by Optical Coherence Tomography(OCT).</measure>
    <time_frame>6 month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To investigate the Foresee PHP ability to asses treatment progression post treatment.</measure>
    <time_frame>6 month</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">15</enrollment>
  <condition>Age Related Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <description>Subjects diagnosed as new CNV or treated CNV</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PHP - Preferential Hyperacuity Perimeter (Foresee)</intervention_name>
    <description>computerized test</description>
    <arm_group_label>1</arm_group_label>
    <other_name>PHP 2.0.5</other_name>
    <other_name>OCT - optical coherence tomography</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        -  Subjects diagnosed as new CNV or treated CNV&#xD;
&#xD;
          -  Age &gt;50 years&#xD;
&#xD;
          -  VA with habitual correction &lt;20/160 in the study eye&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Capable and willing to sign a consent form and participate in the study&#xD;
&#xD;
          -  Subjects diagnosed as new CNV or treated CNV&#xD;
&#xD;
          -  Age &gt;50 years&#xD;
&#xD;
          -  VA with habitual correction &lt;20/160 in the study eye&#xD;
&#xD;
          -  Ability to understand instructions&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Evidence of macular disease other than AMD or glaucoma in the study eye&#xD;
&#xD;
          -  Presence of any significant media opacity that precludes a clear view of the macular&#xD;
             area as identified in the study eye by biomicroscopy,&#xD;
&#xD;
          -  Any non-macular related ocular surgery performed within 3 months prior to study entry&#xD;
             in the target eye&#xD;
&#xD;
          -  Patients diagnosed with geographic atrophy (GA)&#xD;
&#xD;
          -  Participation in another study with the exclusion of AREDS study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anat Loewenstein, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sorasky Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sorasky Medical center</name>
      <address>
        <city>Tel Aviv</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <link>
    <url>http://www.notalvision.com</url>
    <description>sponsor web site</description>
  </link>
  <verification_date>January 2009</verification_date>
  <study_first_submitted>May 26, 2008</study_first_submitted>
  <study_first_submitted_qc>June 5, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 6, 2008</study_first_posted>
  <last_update_submitted>January 27, 2009</last_update_submitted>
  <last_update_submitted_qc>January 27, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 28, 2009</last_update_posted>
  <responsible_party>
    <name_title>Osnat Ehrman</name_title>
    <organization>Notal Vision</organization>
  </responsible_party>
  <keyword>AMD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

